Belantamab Mafodotin in Myeloma: Can a Questionnaire Replace Eye Exams? | IMS 2026

Rakesh Popat, MD, PhD, of University College London Hospitals discusses interim results from the ProMMise study of a vision questionnaire to guide belantamab mafodotin (Blenrep) treatment at IMS 2026 in Glasgow. Patients on belantamab usually need regular eye exams, which add to treatment burden. In 40 patients, a short questionnaire caught nearly all severe eye problems, though it also flagged some false alarms. The next stage will test whether the questionnaire alone can replace routine eye exams.

If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu

For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity

Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!

Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general

Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.

Timestamps:

0:00 Introduction: Dr. Rakesh Popat, University College London Hospitals

0:08 The ProMMise Trial and Belantamab Mafodotin

0:31 How Belantamab Works as an Antibody-Drug Conjugate

1:01 Eye Problems and the Burden of Ocular Exams

1:23 The VRAT Questionnaire: How the Study Worked

2:15 Results: Catching Severe Eye Problems

2:47 False Positives and the Need for Training

3:18 What's Next: Stage 2 Without Eye Exams